@BioPharmaMrkt@adamfeuerstein The average time for an MHRA marketing authorisation approval for new generic applications is 210 days, and for biosimilars it is 180 days. NWBO 1000 days coming up?
@StockChaser_ NVO definitely has the lower valuation, so looks to be the better buy. Perhaps some Greenland/Denmark future tariff threat built in? Or, ... pay a little more for the leader being LLY.
@1000xStocks $AMD
If you are genuinely seeking a stock with 1000x potential β¦. $NWBO. 10x at MHRA approval. 100x potential with a short squeeze. 1000x β¦ long term with many hurdles. Outside chance, but still a chance.